Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma

THOUSAND OAKS, Calif. and INGELHEIM, Germany, Sept. 1, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced thatAmgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836909 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. BI 836909 (AMG 420) is currently in Phase 1 studies. BI 836909 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired by Amgen in 2012.



Amgen - Investors - RSS Content